Mercer Global Advisors
LUCD icon

Mercer Global Advisors’s Lucid Diagnostics LUCD Stock Holding History

Mercer Global Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$21.2K Buy
+19,784
New +$21.3K ﹤0.01% 4791

Other funds holding LUCD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Mercer Global Advisors's LUCD Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in Lucid Diagnostics (LUCD) in Q2 2026: 19,784 shares worth $21.2K. The stake represents ﹤0.01% of the portfolio and ranks #4791 among its holdings.

95 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Mercer Global Advisors held 19,784 shares of Lucid Diagnostics worth $21.2K as of Q2 2026.
  • Lucid Diagnostics was a new Mercer Global Advisors position in Q2 2026.
  • Lucid Diagnostics made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #4791 holding.
  • 95 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.